LYSRUPTO

Pharmaceutical preparations for the treatment of Gram-positive bacterial infection, including, but not limited to, Staphylococcus aureus infection; pharmaceutical preparations for the treatment of drug-resistant strains of bacteria, including antibiotic-resistance bacterial infection; and pharmaceutical preparations for the treatment of infections related to Gram-positive bacteria and drug-resistant strains of bacteria, including, but not limited to, Staphylococcus aureus blood stream infections, Staphylococcus aureus bacteremia and endocarditis, including, but not limited to, right-sided infective endocarditis, including right-sided infective endocarditis caused by methicillin-susceptible and methicillin-resistant isolates